Connor J Kinslow, Giuseppe Minniti, Paul D Brown, Michael A Vogelbaum, Karla V Ballman, Ann Mercurio, Markus D Siegelin, Emre Kocakavuk, Kyle Tuohy, Alireza Mansouri, Mehdi Touat, François Ducray, Caroline Dehais, Angelo Dipasquale, Matteo Simonelli, David M DeStephano, Jack Grinband, James B Yu, Henry Walch, Mitchell I Parker, Igor Shuryak, Soumyajit Roy, Shawn L Hervey-Jumper, Matthew Gallitto, David P Horowitz, Guy M McKhann, Michael B Sisti, Jeffrey N Bruce, Peter Canoll, Quinn T Ostrom, Alfred I Neugut, Luke R G Pike, Fabio M Iwamoto, Simon K Cheng, Lisa A Kachnic, Minesh P Mehta, Tony J C Wang
In the absence of additional clinical or molecular risk factors, age alone should not be considered an indication for administration or deferral of adjuvant treatment. Practice guidelines should be revised to reflect contemporary prognostic factors in the molecular era.
PURPOSE: Age ≥40 years is regarded as a high-risk feature and an indication for adjuvant chemoradiotherapy for patients with lower-grade glioma in clinical practice guidelines. It is unclear whether age remains a relevant prognostic factor for contemporary definitions of lower-grade gliomas in the molecular era.
METHODS: The Prospective Gliomas Research (PROGRES) database contains individual patient-level data from 11 prospective clinical trials or observational registries of histologically defined lower-grade 2-3 oligodendroglioma or astrocytoma. We determined the association of age (18-39 years v ≥40 years) with progression-free survival (PFS) stratified by isocitrate dehydrogenase 1 or 2 (IDH1/2) status, using log-rank tests and Cox regression models. We validated our findings in a separate multi-institutional retrospective cohort (Retrospective Glioma Research [REGRES] database).
RESULTS: We identified 1,619 and 1,292 eligible patients in the PROGRES and REGRES cohorts, respectively. IDH-wildtype tumors were more common in patients 40 years and older (38% v 5%, odds ratio: 11.3 [95% CI, 6.5 to 19.7]). Age was associated with PFS in IDH-wildtype (5-year PFS for ≥40 v 18-39 years: 6% v 24%, hazard ratio [HR], 1.74 [95% CI, 1.21 to 2.50]) but not in IDH-mutant glioma (60% v 59%, HR, 0.89 [95% CI, 0.76 to 1.05], Pinteraction < .001). In IDH-wildtype tumors, older age predicted aggressive molecular features, including TERT promoter mutation (65% v 28%), EGFR amplification (41% v 15%), and chromosome +7/-10 alteration (57% v 25%). In a pooled analysis of four clinical trials, age was not predictive of a benefit from chemoradiotherapy versus radiotherapy alone for IDH-mutant glioma.
CONCLUSION: In the absence of additional clinical or molecular risk factors, age alone should not be considered an indication for administration or deferral of adjuvant treatment. Practice guidelines should be revised to reflect contemporary prognostic factors in the molecular era.